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A chemically diverse library of TAGE-triazole conjugates was synthesized utilizing click chemistry on
the TAGE scaffold. This library of small molecules was screened for anti-biofilm activity and found to
possess the ability of inhibiting biofilm formation against Acinetobacter baumannii, Staphylococcus
aureus and Pseudomonas aeruginosa. One such compound in this library demonstrated the most potent
inhibitory effect against Staphylococcus aureus biofilm formation that has been displayed by any
2-aminoimidazole derivative.
Introduction
Recent findings in biomedical research have revealed that biofilm-
mediated infections play a prominent role in infectious disease.1
Bacterial biofilms are defined as highly structured communities
of microbial cells attached to a surface and encased in a
protective matrix made primarily of polysaccharide material.2
Biofilm formation occurs when free-swimming planktonic cells
collectively coordinate their behavior through a communication
pathway involving signaling molecules, termed quorum sensing,
resulting in their attachment to a surface and colonization.3–5 Once
a biofilm is established, these bacteria act as if they were a multi-
cellular organism resulting in the virulent phenotypes associated
with various biofilm-mediated diseases. Despite their prevalence,
biofilm-associated infections have been a medical obstacle due to
their increased resistance to conventional antibiotics as well as
host immune responses.6
There have been relatively few small molecules identified that
possess anti-biofilm activity, with anti-biofilm activity defined as
modulating biofilm development through non-toxic mechanisms.
Examples of compounds possessing anti-biofilm activity include
derivatives of homoserine lactones,7 which are endogenous signal-
ing molecules used by bacteria in quorum sensing,8,9 brominated
furanones which are natural products isolated from the macroagla
Delisea pulchra,10 as well as ursine triterpenes from the plant
Diospyros dendo.11 Recently, Junker and Clardy reported the
development of a high throughput screen revealing several small
molecules capable of inhibiting Pseudomonas aeruginosa biofilms
(Fig. 1).12
Our group has recently developed several novel libraries of 2-
aminoimidazole small molecules inspired by the marine alkaloids
bromoageliferin 6 and oroidin 10.13–19 These natural products were
previously reported to inhibit biofilm formation of the marine a-
protobacterium Rhodospirillum salexigens.20 TAGE and CAGE
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Fig. 1 Previously reported biofilm inhibitors.
were the first documented 2-aminoimidazoles with anti-biofilm
activity against Pseudomonas aeruginosa biofilms (Fig. 2).13
Fig. 2 Representative 2-aminoimidazoles derived from the marine natu-
ral products bromoageliferin 6 and oroidin 10.
Analogues of the structurally simpler alkaloid oroidin were
also pursued to develop novel classes of small molecules with
anti-biofilm activity. Recently, an oroidin inspired library was
constructed utilizing click chemistry to generate a diverse library of
2-aminoimidazole/triazole conjugates (2-AIT). These compounds
displayed the widest spectrum of anti-biofilm activity observed
within the 2-aminoimidazole class (Fig. 2, 11).18
Based on the potent activity displayed by 2-AIT conjugates,
we decided to explore if triazole incorporation within the TAGE
scaffold would lead to compounds with enhanced anti-biofilm
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activity. To accomplish this goal, we postulated that epoxide 12
could be synthetically elaborated to AzidoTAGE 13 (Fig. 3). The
appending azides were designed to serve as synthetic handles for
derivatization using click chemistry to generate a TAGE-triazole
library.
Fig. 3 Synthetic approach to the construction of a TAGE-triazole library
from previously reported epoxide 12.
Results and discussion
Synthesis of TAGE-triazole library
The assembly of the TAGE-triazole library was initiated by
refluxing epoxide 12 in a 1:1 mixture of aqueous ammonium
hydroxide and methanol saturated with ammonia for 5.5 hours
in a sealed tube (Scheme 1). Acid-base extraction yielded the pure
aminoalcohol in 97% yield. The resulting amine was then Boc-
protected (99% yield) and further subjected to PDC oxidation
to give Boc-protected a-aminoketone 15 in 81% yield. The Boc-
group was then removed upon treatment with TFA followed
by subsequent addition of HCl in methanol to effect counter
ion exchange. This resulting a-aminoketone · HCl salt was then
dissolved in water followed by the addition of cyanamide and the
pH of the solution was adjusted to 4. This reaction was heated to
95 ◦C for 2.5 hours, delivering AzidoTAGE 13 in 79% yield over
2 steps as the HCl salt.
Scheme 1 Synthesis of AzidoTAGE 13. Reaction conditions: (a) NH4OH,
H2O, MeOH (NH3), reflux, 97% (b) Boc2O, acetone, H2O, Na2CO3, reflux,
99% (c) PDC, DMF, room temp, 81% (d) TFA, CH2Cl2, 0 ◦C to room
temp (e) NH2CN, H2O, pH 4, 95 ◦C, 79%.
Although this library was designed to combine the 1,2,3-triazole
element of the 2-AIT library with the TAGE scaffold,18 this new
platform is chemically distinct from our previous approach to 2-
AIT conjugates in that the azides are on the core TAGE scaffold
bearing the 2-aminoimidazole. In the 2-AIT library, the terminal
alkyne is on the core scaffold with the 2-aminoimidazole. This
reversal in click partners allows easier access to a chemically
diverse library since most of the azides of the 2-AIT library
required synthesis from the corresponding alcohols. The majority
of terminal alkynes in this study were commercially available.
Alkynes that were not commercially available required only one
step and were purified by recrystallization.
The click reaction was carried out in the presence of the HCl salt
of AzidoTAGE 13. The click conditions we employed for this study
relied on a 1:1:1 ratio of ethanol:water:dichloromethane, copper
sulfate (15 - 30 mol%) and sodium ascorbate.18 These reactions
were typically carried out overnight at room temperature (16–
24 hours). The alkynes chosen for this study vary from being
structurally simple hydrocarbon chains to those decorated with
brominated pyrrole rings. These TAGE-triazole small molecules
provided the necessary diversity to attain a preliminary insight into
the SAR of TAGE-triazole conjugates in the context of biofilm
inhibition and dispersion. These conditions were shown to be
general, allowing the construction of a chemically diverse 21-
membered TAGE-triazole library (Table 1). The TAGE-triazole
library is composed of four series, which are classified according to
the structural variation of the triazole moiety as the hydrocarbon
chain series, cycloalkyl series, phenyl series and amide series.
Biofilm inhibition studies
The TAGE-triazole library was initially screened for anti-biofilm
activity against Acinetobacter baumannii. A. baumannii is a Gram-
negative bacterium recognized by the medical field for its role in
nosocomial infections. Infections acquired from A. baumannii are
difficult to treat because they are resistant to many antibiotics, such
as penicillin, chloramphenicol and often aminoglycosides.21 This
multidrug-resistance (MDR) is attributed to active drug efflux
ability. A. baumannii elicits its pathogenicity through biofilm-
mediated virulence and tests positive in 25% of all hospital swabs
in both the US and Europe.22,23
The TAGE-triazole library members were initially screened at
400 mM to eliminate weakly active or inactive TAGE-triazole
conjugates. Inhibition screens were run using PVC microtiter
plates in a 96-well format. The inside of these wells serves as a
surface for biofilm attachment and development during bacterial
growth. The amount of biofilm that forms on the inside of these
wells is quantified by using a crystal violet reporter assay.13 These
values then serve as a point of comparison to identify lead biofilm
inhibitors. This approach quickly eliminated six compounds that
were not able to inhibit biofilm formation by 50% at 400 mM (H5,
C1, P2, A1, A2, A3). Dose-response curves were then generated
for the remaining 15 compounds to determine their respective IC50
values (Table 2).
In the series of simple hydrocarbon chains we noted that the
inhibitory activity was dependent on chain length and branching
(Fig. 4). Using analogue H1 as our point of reference, extension
of the hydrocarbon chain one methylene unit from butyl H1 to
pentyl H2 increased inhibition activity significantly. The IC50
of H1 was measured as 161 ± 25 mM, while H2 was 59.6 ±
2.8 mM. Inhibition activity is increased again by extending the
pentyl side chain (H2) to the hexyl chain (H3). The IC50 value of H3
was determined to be 51.7 ± 4.7 mM. Extending the hydrocarbon
chain one more methylene unit from H3 gave the heptyl derivative
H4 which showed a decrease in activity (IC50 value of 74.1 ±
5.0 mM). Following this structural trend, the decyl side of H5
showed very weak inhibition activity with only 21% inhibition
at 400 mM. Branching of the butyl side chain with the 3-methyl
group of H6 increased the inhibition activity 3-fold compared to
the parent butyl chain H1. This simple 3-methyl addition to the
butyl chain gave an IC50 value of 57.5 ± 12 mM. The t-butyl side
chain of H7 resulted in a slight decrease of inhibition activity
giving an IC50 value of 188 ± 26 mM.














































Table 1 Synthesis of the TAGE-triazole library


























Table 2 Initial screen of the TAGE-triazole library for biofilm inhibition
against Acinetobacter baumannii ATCC 19606
TAGE-triazole % Inhibition at 400 mM
H1 83 ± 3
H2 99 ± 1
H3 96 ± 2
H4 98 ± 1
H5 21 ± 1
H6 97 ± 1
H7 76 ± 9
C1 30 ± 6
C2 98 ± 1
C3 99 ± 1
C4 99 ± 1
C5 81 ± 3
P1 70 ± 7
P2 16 ± 4
P3 77 ± 4
P4 98 ± 1
P5 91 ± 1
A1 3 ± 1
A2 7 ± 2
A3 49 ± 4
A4 84 ± 4
The cycloalkyl series also provided structural insight into
inhibiting A. baumannii biofilm formation. We began by deter-
mining the activity of the cyclopentyl derivative C2 which gave
an IC50 value of 79.5 ± 9.5 mM. When a methylene linker was
Fig. 4 Structures and biofilm inhibition activity against A. baumannii of
the TAGE-triazole hydrocarbon chain series.
inserted between the triazole and cyclopentyl ring to give C4 the
activity was essentially identical, giving an IC50 value of 75.1 ±
5.7 mM. Trading out a 5-membered ring for the 6-membered
ring in C3 gave a slight increase in activity with a measured














































IC50 value of 63.9 ± 5.7 mM. Placement of a methylene spacer
between the triazole ring and the cyclohexyl ring (C5) greatly
reduced inhibition activity as demonstrated by an IC50 value of
127 ± 14 mM (Fig. 5). Cyclopropyl derivative C1 demonstrated
weak biofilm inhibition activity against A. baumannii, inhibiting
30% of biofilm formation at 400 mM.
Fig. 5 Structures and biofilm inhibition activity against A. baumannii of
the TAGE-triazole cycloalkyl series.
The third class of TAGE-triazoles was based on substituted
phenyl derivatives. The phenyl ring derivative P1 gave an IC50
value of 120 ± 29 mM against A. baumannii biofilm formation.
Changing the electronics of the phenyl ring was investigated by
adding a 4-methoxy group to the phenyl ring giving P2. This
greatly decreased the inhibition activity and only 16% biofilm
inhibition was observed at 400 mM. Extending the phenyl ring out
by adding the methylene unit in P3 also decreased the activity
slightly (IC50 = 165 ± 12 mM). However, extending the phenyl
ring by two methylene units in P4 greatly increased the activity
giving the best inhibitor in the phenyl ring series with an IC50
value of 61.5 ± 10 mM. Substituting the second methylene unit
from the triazole of this active structure with an oxygen atom in
P5 decreased the activity from the lead ethyl spacer within this
series by giving an IC50 value of 80.1 ± 9.5 mM (Fig. 6).
Within the amide series of the TAGE-triazole library, the
only active member against A. baumannii biofilm formation was
A4 (Fig. 7). The activity of this small molecule was surprising
considering the importance of 2-aminoimidazole dibromopyrrole
conjugates as biofilm modulators.14,16,17,19 The IC50 value for A4
was determined to be 48.8 ± 8.6 mM. The other members of the
amide series demonstrated weak inhibitory activity at 400 mM.
When comparing the relatively complex structure of A4 to
a previous TAGE derivative, DibromoTAGE 7, the inhibition
activity drops 3-fold when compared to the previously reported
IC50 value of 15.5 mM against A. baumannii.16 This drop in activity
may be attributed to the unoptimized head-to-tail distance from
the 2-aminoimidazole head to the dibromopyrrole tail in this
structure. Previous studies in our labs have shown that the anti-
biofilm activity is dependent on the relative distance between the
2-aminoimidazole moiety and either dibromopyrrole or triazole
heterocycles.17,18
Fig. 6 Structures and biofilm inhibition activity against A. baumannii of
the TAGE-triazole phenyl ring series.
Fig. 7 Structures and biofilm inhibition activity against A. baumannii of
the TAGE-triazole amide series.
Each compound that was able to generate an IC50 value below
400 mM against A. baumannii was tested against planktonic
bacteria to determine if these small molecules elicited their effects
through a toxic mechanism. These compounds were added to a
test tube at the IC50 value and optical densities of the treated and
untreated samples were monitored after 1, 3, 5, 7 and 24 hours.
After 5 and 7 hours, some TAGE-triazole library members show a
slight reduction in the bacterial growth of A. baumannii, indicating
some bacterial static effects, however, after 24 hours, there was no
reduction in the optical densities between treated and untreated
planktonic growth.
The next opportunistic bacterium we investigated was Staphly-
ococcus aureus, a Gram-positive bacterium responsible for many














































Table 3 Initial screen for biofilm inhibition against Staphylococcus aureus
ATCC 29213
TAGE-triazole % Inhibition at 400 mM
H1 47 ± 6
H2 22 ± 7
H3 93 ± 1
H4 98 ± 1
H5 No activity
H6 99 ± 1
H7 95 ± 1
C1 No activity
C2 95 ± 3
C3 71 ± 5
C4 33 ± 9
C5 76 ± 8
P1 22 ± 1
P2 95 ± 4
P3 76 ± 6
P4 97 ± 2




A4 93 ± 3
nosocomial infections. S. aureus is notorious for being multi-drug
resistance against several classes of antibiotics (i.e. penicillins,
aminoglycosides, glycopeptides). Methicillin-resistant Staphylo-
coccus aureus (MRSA) and Vancomycin-resistant Staphylococcus
aureus (VRSA) are two examples of strains that have developed
resistance to conventional antibiotics.24 Given that S. aureus
forms robust biofilms, we screened our TAGE-triazoles to identify
possible inhibitors of biofilm formation. As with A. baumannii, we
initially screened this library at 400 mM (Table 3).
From this initial screen eight compounds (H3, H4, H6, H7,
C2, P2, P4, A4) demonstrated greater than 90% inhibition and
were further evaluated in inhibition screens. Four of the active
TAGE-triazoles were from the hydrocarbon series, one from the
cycloalkyl series, two from the phenyl ring series and one from the
amide series (Fig. 8).
Fig. 8 IC50 values for the active TAGE-triazoles against Staphylococcus
aureus.
Interestingly P2, which showed only 16 ± 4% inhibition at
400 mM against A. baumannii, gave 95 ± 4% inhibition at 400 mM
against S. aureus biofilm formation and upon further evaluation
gave an IC50 value of 118 ± 13 mM. However, when tested for
bactericidal activity, growth curves with P2 indicated a reduction
in cellular density of about 25% at the 24 hour time point although
there was no reduction during exponential growth. Although
several of these compounds were shown to effect bacterial growth
TAGE-triazoles H7, C2, P4 and A4 showed no reduction in
bacterial density in the growth curves.
TAGE-triazole A4 demonstrated the most potent inhibitory
effect of any 2-aminoimidazole derivative thus far against S. aureus
with an IC50 value of 141 ± 28 nM. We felt that this small molecule
would be very effective in inhibition screens since DibromoTAGE
7 was reported to give good inhibition against S. aureus (IC50
value of 14.0 mM),16 but some of this activity was occurring by
inhibition of bacterial growth. However, the insertion of a triazole
moiety adjacent to the dibrominated pyrrole carboxyamide not
only greatly increases activity (100-fold), but also gives an actual
biofilm inhibitor that elicits its anti-biofilm activity through non-
toxic means as well as providing the first 2-aminoimidazole with a
TAGE scaffold to report an IC50 value in the nanomolar range.
Finally, we looked to see if this TAGE-triazole library was able
to demonstrate anti-biofilm activity against Pseudomonas aerugi-
nosa, a Gram-negative, opportunistic bacterium most commonly
known for causing morbidity in nearly all those predisposed to
the genetic disease that causes cystic fibrosis (CF). This biofilm-
forming bacterium is also a threat for infection in burn victims
as well as those who are immunocompromised.25 P. aeruginosa is
notorious for being multidrug-resistant against many antibiotics
as well. There are several mechanisms by which this bacterium
evades the action of antimicrobial agents: restricted uptake,
multidrug efflux pumps, and the use of chromosomally-encoded
antibiotic resistance genes which occur naturally and can be
acquired via horizontal gene transfer.26
During the course of our studies with P. aeruginosa we have
observed PAO1 and PA14 to be capable of forming a very dense
biofilm at room temperature compared to biofilms formed at
37 ◦C (Fig. 9). Based upon this observation we decided to screen
the TAGE-triazole library against PAO1 at room temperature.
When inhibition screens are carried out at 37 ◦C, TAGE 8 was
reported to inhibit PAO1 biofilm formation giving an IC50 value
of 100 mM.13 DibromoTAGE 7 demonstrated a 50-fold increase in
biofilm inhibition activity against PAO1 (IC50 value of 1.77 mM)
compared to TAGE 8.16
Fig. 9 Quantification of biofilm formation by crystal violet staining of
microtiter wells at room temperature and 37 ◦C.
These small molecules were screened at room temperature to
demonstrate the difference temperature has on the inhibition of
P. aeruginosa biofilm formation. TAGE 8 and DibromoTAGE 7
gave IC50 values of 361 ± 9.5 mM and 15.8 ± 0.7 mM respectively.
This is about a 4- to 8-fold higher IC50 value then those observed
at 37 ◦C. These values correspond to the increase in biofilm
formation at room temperature. Based upon this observation,
we screened the library at an initial concentration of 500 mM
to identify preliminary hits at room temperature.














































Table 4 Biofilm inhibition activity against PAO1 at room temperature
TAGE-triazole % Inhibition at 500 mM
H3 99 ± 1
C3 96 ± 1
P1 96 ± 2
C4 75 ± 1
H2 62 ± 5
H6, P5 45 ± 8
P3 33 ± 4
C1 28 ± 9
P4 27 ± 8
H4 22 ± 2
A1 20 ± 5
P2 19 ± 4
H1, C5, H7 <10
C2, H5, A2, A3, A4 No activity
The results of the initial screen at 500 mM are shown in Table 4.
Three members of this library (H3, C3, P1) demonstrated >95%
inhibitory activity against PAO1 at 500 mM. A4 demonstrated no
inhibition activity at 500 mM. This was surprising since it closely
resembles the structure of DibromoTAGE 7.
We then set out to determine the IC50 value of H3 against
both PAO1 and PA14 with the newly adopted inhibition screen
at room temperature to compare this small molecule to TAGE 8
and DibromoTAGE 7. The IC50 values of H3 were determined to
be 98.5 ± 10.9 mM and 60.2 ± 2.6 mM against PAO1 and PA14
respectively.
TAGE-triazole H3 was also determined to be acting through
a non-toxic mechanism by not killing planktonic bacteria as
demonstrated by the growth curves of PAO1 and PA14 after
24 hours. The lead TAGE-triazole H3 demonstrated inhibition
potency against PAO1 and PA14 that was an improvement on that
of TAGE 8, however, it does not possess biofilm inhibition activity
greater than that of DibromoTAGE 7.
Conclusions
This novel TAGE-triazole library was constructed utilizing the
click reaction to generate a chemically diverse library of small
molecules from commercially available or easily prepared terminal
alkynes. The implementation of this synthetic route has proven to
be an effective approach in generating a chemically diverse set of
small molecules possessing structural elements of the biologically
active marine alkaloid, bromoageliferin, while tuning the activity
with structural variations dictated by the terminal alkyne click
partner. Several of these TAGE-triazole compounds were shown
to be capable of inhibiting the formation of A. baumannii, S. aureus
and P. aeruginosa biofilms. TAGE-triazole A4 has demonstrated
the most potent inhibitory response reported thus far against
S. aureus biofilm formation. Further developments concerning
TAGE-triazole small molecules are underway in our labs and will
be reported in due course.
Experimental
Biofilm screening
TAGE-triazole library members were dissolved in DMSO, filtered
through Whatman 13 mm GD/X syringe filters and stored as
either 50 or 100 mM solutions at -20 ◦C until needed for biological
study. The DMSO used in these biofilm inhibition screens did not
exceed 1% by volume and had no effect on bacterial growth or
biofilm formation. Acinetobacter baumannii and Staphylococcus
aureus were purchased from ATCC. Pseudomonas aeruginosa
strains PA01 and PA14 were donated by Dr. Daniel Wozniak at
Wake Forest University School of Medicine.
A. baumannii (ATCC 19606) was grown in LB media during the
course of this study for inhibition assays and analysis of growth
curves. S. aureus (ATCC 29213) was grown in Tryptic Soy Broth
supplemented with 0.3% glucose. PAO1 and PA14 utilized LBNS
(LB “No Salt”) as the media for this study.
Static biofilm inhibition assay
An overnight culture of bacterial strain was subcultured at an
OD600 of 0.01 into the media used depending on bacterial strain.
This was pipetted into test tubes along with a predetermined
concentration of the compound tested. The contents of the test
tubes were then poured into tilted Petri dishes and 100 mL of
medium, bacteria and compound were then transferred into 96-
well PVC microtiter plates. These microtiter plates were then
covered with a plastic lid, wrapped in Saran wrap and incubated at
either room temperature or 37 ◦C for 24 hours. After incubation,
the medium was discarded and the plates were vigorously washed
twice with water. The remaining biofilm that formed during
incubation was stained with 100 mL of a 0.1% crystal violet
solution and allowed to sit at room temperature for 30 minutes.
After 30 minutes, the crystal violet was discarded and washed
thoroughly again with water. The remaining crystal violet which
stained the biofilm on the inside of the wells was solubilized
with 200 mL of 95% ethanol. The quantification of biofilm
formation was accomplished by transferring 125 mL of the ethanol
solution into a polystyrene microtiter dish, which was read by
spectrophotometry (A540). After subtracting the background from
each row, a percent inhibition could be calculated by dividing
the amount of crystal violet stain in the wells that contained
compound by the amount of crystal violet stain in wells that
contained bacteria only. Each concentration reported during the
course of this study was repeated two to four times with each
biofilm inhibition assay being done in 6 or 8 replicates each.
The inhibition effectiveness was plotted to generate a 5 to 8
point curve of the percent inhibition of biofilm formation versus
the concentration of compound tested. This curve was used to
determine IC50 values.
Growth curves
An overnight culture of bacterial strain was subcultured into its
respective media at an OD600 of 0.01. The inoculated media (3 ml)
was added to two test tubes, one that would not be treated, to serve
as a control for bacterial growth, and one that would be treated
with a member of the TAGE-triazole library at the IC50 value.
The test tubes were shaken while incubated and bacterial growth
was monitored at 1, 3, 5, 7 and 24 hours. These experiments were
done from three different overnight cultures from three different
bacterial colonies in single replicate.














































Note: A. baumannii and S. aureus strains were shaken at 200 rpm
at 37 ◦C in their respective media. PAO1 and PA14 were agitated
at 350 rpm at room temperature in LBNS.
Chemistry
All chemicals and solvents used for the chemical synthesis of
the TAGE-triazole library were purchased from commercially
available sources and used without further purification. Silica
gel was used for column chromatography and was performed
with 60 Å mesh standard grade silica gel from Sorbtech. 1H and
13C NMR spectra were preformed using Varian 300 MHz and
400 MHz spectrometers. Chemical shifts are reported in parts
per million relative to CDCl3 (d 7.26), CD3OD (d 4.78 or 3.31)
and DMSO-d6 (d 2.50) for 1H NMR and relative to CDCl3 (d
77.23), CD3OD (d 49.51) and DMSO-d6 (d 39.51) for 13 C NMR
with TMS as an internal standard. High-resolution mass spectra
were obtained at the North Carolina State Mass Spectrometry
Laboratory for Biotechnology.
trans-2-Amino-trans-4,5-bis(azidomethyl)cyclohexanol. 2.889 g
(13.9 mmol) of epoxide 12 was added to a stirring solution of
aqueous NH4OH (80 ml) in a sealed tube. Ammonia-saturated
methanol (80 ml) was then added to completely dissolve the
starting material. The tube was then sealed and refluxed for
5.5 hours. The reaction was then cooled in an ice bath before
removal of the seal. The reaction was then concentrated under
vacuum pressure to give a dark yellow residue. The resulting amine
was purified by acid-base extraction by adding 5% HCl (aq) to
the residue. The organic layer was collected and discarded. The
acidic aqueous layer was then treated with 10% NaOH (aq) until
the aqueous layer was basic and the organic layer was collected,
dried with sodium sulfate and concentrated to give 3.024 g (97%
yield) of a light yellow residue as a free base of the aminoalcohol
product. 1H NMR (300 MHz, CD3OD) d 3.48 (m, 1H), 3.39 (m,
4H), 3.27 (m, 4H), 2.74 (bs, 1H), 1.93–1.70 (m, 4H), 1.62–1.45 (m,
2H); 13C NMR (100 MHz, CD3OD) d 71.9, 55.6, 55.5, 52.5, 36.3,
35.7, 32.4, 31.8; HRMS (ESI) calculated for C8H16N7O (MH+)
226.1410, found 226.1409.
tert -Butyl - trans -4 ,5 -bis (azidomethyl ) -2 -hydroxycyclohexyl-
carbamate. Di-tert-butyl dicarbonate (4.392 g, 20.1 mmol) was
added to a stirred solution of 3.024 g (13.5 mmol) of the
aminoalcohol product from the previous step in acetone (50 ml)
and distilled water (30 ml). Then 4.951 g of sodium carbonate
(46.7 mmol) was added and the reaction was refluxed for 1 hour.
The reaction was quenched with brine and upon cooling the
reaction was added to a separatory funnel and extracted with
ethyl acetate. The organic layer was washed two times with brine
and collected. After drying the organic layer with sodium sulfate
the organic layer was concentrated to give 4.355 g (99% yield) of
the Boc-protected aminoalcohol as a yellow oil which required
no further purification. 1H NMR (300 MHz, CDCl3) d 4.83 (bs,
1H), 3.76 (m, 1H), 3.61 (m, 1H), 3.44–3.25 (m, 4H) 1.92–1.82 (m,
2H), 1.63–1.46 (m, 4H), 1.39 (s, 9H); 13C NMR (75 MHz, CD3Cl)
d 155.9, 79.9, 67.9, 54.4, 54.3, 34.3, 33.7, 31.6, 29.0, 28.4, 27.3;
HRMS (ESI) calculated for C13H23N7O3Na (MNa+) 348.1754,
found 348.1754.
tert -Butyl-trans-4,5-bis(azidomethyl)-2-oxocyclohexylcarba-
mate (15). 404 mg (1.24 mmol) of the Boc-protected aminoal-
cohol synthesized in the previous step was dissolved in 12 ml
DMF. PDC (2.867 g, 7.63 mmol) was then added and the reaction
was allowed to stir at room temperature for 24 hours. The reaction
was quenched with brine and extracted with ethyl acetate. The
organic layer was then washed two times with brine. Sodium
sulfate was added to dry the organic layer. Then the organic layer
was concentrated and purified by flash column chromatography
using 5:1 hexanes:ethyl acetate to afford 328 mg (81% yield) of 15
inseparable epimers as a clear oil. 1H NMR (300 MHz, CDCl3)
d 5.47–5.35 (m, 1H), 4.23 (m, 1H), 3.61 (m, 1H), 3.52–3.24 (m,
3H), 2.61–2.50 (m, 1H), 2.49–2.34 (m, 2H), 2.09 (m, 1H), 1.94
(m, 1H), 1.73–1.68 (m, 1H), 1.43 (s, 9H); 13C NMR (75 MHz,
CD3Cl) d 205.9, 205.2, 155.2, 79.9, 77.4, 57.9, 55.2, 54.1, 53.8,
53.4, 53.1, 43.3, 40.5, 39.5, 38.4, 37.9, 37.0, 34.8, 33.1, 28.4,
28.3, 27.7; HRMS (ESI) calculated for C13H21N7O3Na (MNa+)
323.1706, found 323.1713.
AzidoTAGE (13). To a stirred solution of 15 (437 mg,
1.34 mmol) in methylene chloride was added 4 ml of TFA dropwise
at 0 ◦C. The reaction continued to stir at 0 ◦C for one hour and
then was allowed to warm to room temperature for an additional
one hour. The reaction was then concentrated and a solution of
HCl in methanol was added and concentrated overnight. Distilled
water was added (8 ml) and a 50% cyanamide solution (50% by
weight, 500 mg) was added to the residue and heated to 95 ◦C
for 2.5 hours. The pH was 4 for this reaction and required no
additional adjustments. The reaction was then allowed to cool
and ethanol was added to assist the concentration of this aqueous
mixture under high vacuum pressure. It was necessary to wash the
residue with ether (2 ¥ 150 ml) before column chromatography.
AzidoTAGE (13) was purified by flash column chromatography
using 10% methanol/ammonia in methylene chloride to afford an
orange foam. After 48 hours on a high vacuum pump to remove all
residual ammonia, 13 was then acidified using HCl in methanol
to give 304 mg (79% yield) as a light yellow foam. 1H NMR
(400 MHz, DMSO-d6) d 11.75 (s, 2H), 7.42 (s, 2H), 3.55–3.38
(m, 4H), 2.29 (m, 2H), 2.24 (m, 2H), 2.02 (m, 2H); 13C NMR
(100 MHz, CD3OD) d 148.4, 119.8, 54.6, 36.5, 23.2; HRMS (ESI)
calculated for C9H14N9 (MH+) 248.1366, found 248.1365.
General procedure for click reaction
To a vial with 60–80 mg of AzidoTAGE·HCl was added 1 ml of
ethanol, 1 ml of distilled water and 1 ml of methylene chloride.
A stir bar was added and the mixture was stirred to dissolve
the starting AzidoTAGE·HCl. Then 6 to 15 equivalents of the
predetermined alkyne were added to the reaction mixture. Then
30 to 60 mol% of sodium ascorbate relative to the alkyne was
added and allowed to dissolve. Finally CuSO4 was added to
the reaction mixture and the reaction stirred overnight (16–
24 hours). The reaction was stopped by adding methanol and
transferring to a round bottom flask where the contents were
concentrated under high pressure vacuum and the resulting
residue was purified by flash column chromatography using 1:15
methanol/NH3:methylene chloride as the solvent and increasing
the methanol/NH3 gradually to 1:4 until the purified TAGE-
triazole analogue was collected as the free base.
(H1.) Butyl TAGE-triazole. 1H NMR (300 MHz, CD3OD) d
7.70 (s, 2H), 4.42 (m, 4H), 2.69 (t, J = 7.2 Hz, 6H), 2.35–2.21














































(m, 4H), 1.64 (quintet, J = 7.5 Hz, 4H), 1.35 (sextet, J = 7.4 Hz,
4H), 0.95 (t, J = 7.5, 6H); 13C NMR (300 MHz, CD3OD) d 154.0,
149.9, 123.7, 120.1, 53.1, 37.2, 32.8, 26.1, 23.3, 21.8, 14.1; HRMS
(ESI) calculated for C21H33N9 (MH+) 412.2931, found 412.2930.
(H2.) Pentyl TAGE-triazole. 1H NMR (300 MHz, CD3OD) d
7.71 (s, 2H), 4.44 (m, 4H), 2.68 (t, J = 7.8 Hz, 6H), 2.38 (m, 2H),
2.28 (s, 1H), 2.23 (s, 1H), 1.64 (quintet, J = 7.5 Hz, 4H), 1.33 (m,
8H), 0.92 (t, J = 7.1 Hz, 6H); 13C NMR (100 MHz, CD3OD)
d 149.8, 149.3, 123.8, 119.3, 52.9, 36.9, 32.6, 30.4, 26.4, 23.6,
21.1, 14.5; HRMS (ESI) calculated for C23H38N9 (MH+) 439.3172,
found 439.3162.
(H3.) Hexyl TAGE-triazole. 1H NMR (300 MHz, CD3OD at
4.78 ppm) d 7.63 (s, 2H), 4.37 (m, 4H), 2.61 (m, 6H), 2.28 (s, 2H),
2.20 (s, 1H), 2.14 (s, 1H), 1.56 (m, 4H), 1.27 (m, 12H), 0.83 (m,
6H); 13C NMR (75 MHz, CD3OD) d 151.2, 149.7, 123.7, 122.2,
53.5, 37.6, 32.8, 30.6, 30.0, 26.5, 23.7, 23.0, 14.4; HRMS (ESI)
calculated for C25H42N9 (MH+) 468.3557, found 468.3550.
(H4.) Heptyl TAGE-triazole. 1H NMR (300 MHz, CD3OD)
d 7.70 (s, 2H), 4.41 (m, 4H), 2.67 (m, 6 H), 2.35 (m, 2H), 2.27 (s,
1H), 2.21 (m, 1H), 1.66 (m, 4H), 1.35–1.30 (m, 18H), 0.90 (m, 6H);
13C NMR (75 MHz, CD3OD) d 149.6, 124.0, 123.9, 123.7, 53.5,
37.5, 33.1, 30.7, 30.4, 30.3, 26.4, 23.8, 22.9, 14.6; HRMS (ESI)
calculated for C27H45N9Na (MNa+) 495.3798, found 495.3805.
(H5.) Decyl TAGE-triazole. 1H NMR (300 MHz, CD3OD at
4.78 ppm) d 7.61 (s, 2H), 4.35 (m, 4H), 2.60 (m, 6H), 2.25–2.13 (m,
4H), 1.58 (m, 4H), 1.25 (m, 28H), 0.82 (t, J = 6.6, 6H); 13C NMR
(75 MHz, CD3OD) d 151.3, 149.7, 123.7, 122.2, 53.5, 37.5, 33.2,
30.8, 30.8, 30.7, 30.6, 30.5, 30.4, 26.4, 23.8, 22.9, 14.5; HRMS
(ESI) calculated for C33H58N9 (MH+) 580.4809, found 580.4806.
(H6.) 3-Methylbutyl TAGE-triazole. 1H NMR (300 MHz,
CD3OD at 4.78 ppm) d 7.58 (s, 2H), 4.29 (m, 4H), 2.56 (m, 4H),
2.50 (m, 2H), 2.22 (m, 2H), 2.13 (s, 1H), 2.08 (s, 1H), 1.43 (m, 6H),
0.82 (d, J = 3.0 Hz, 12 H); 13C NMR (75 MHz, CD3OD) d 151.1,
149.8, 123.6, 122.1, 54.9, 54.6, 39.9, 37.6, 36.7, 28.9, 24.4, 22.9;
HRMS (ESI) calculated for C23H37N9 (MH+) 439.3172, found
439.3176.
(H7.) t-Butyl TAGE-triazole. 1H NMR (300 MHz, CD3OD at
3.31 ppm) d 7.72 (s, 2H), 4.48–4.34 (m, 4H), 2.68 (m, 1H), 2.63
(m, 1H), 2.36 (m, 2H), 2.27 (s, 1H), 2.21 (s, 1H), 1.33 (s, 18 s); 13C
NMR (75 MHz, CD3OD) d 159.0, 151.0, 121.9, 121.7, 53.4, 37.5,
31.8, 30.8, 22.6; HRMS (ESI) calculated for C21H33N9Na (MNa+)
434.2751, found 434.2751.
(C1.) Cyclopropyl TAGE-triazole. 1H NMR (400 MHz,
CD3OD at 3.31 ppm) d 7.68 (s, 2H), 4.41 (m, 4H), 2.65 (m, 2H),
2.38–2.22 (m, 4H), 1.96 (m, 2H), 0.96 (m, 4H), 0.77 (m, 4H);
13C NMR (100 MHz, CD3OD) d 151.9, 150.4, 122.6, 121.0, 53.3,
37.2, 22.2, 8.3, 7.4; HRMS (ESI) calculated for C19H25N9 (MNa+)
379.2236, found 379.2233.
(C2.) Cyclopentyl TAGE-triazole. 1H NMR (300 MHz,
CD3OD at 4.78 ppm) d 7.60 (s, 2H), 4.39–4.22 (m, 4H), 3.04
(m, 2 H), 2.55 (m, 2H), 2.24 (bm, 2H), 2.16 (m, 1H), 2.11 (m,
1H), 2.01–1.94 (m, 4H), 1.74–1.52 (m, 12H); 13C NMR (75 MHz,
CD3OD) d 154.0, 151.1, 122.7, 122.0, 53.5, 38.0, 37.5, 34.3, 26.2,
22.9; HRMS (ESI) calculated for C23H33N9Na (MNa+) 458.2751,
found 458.2749.
(C3.) Cyclohexyl TAGE-triazole. 1H NMR (300 MHz,
CD3OD at 3.31 ppm) d 7.68 (s, 2H), 4.39 (m, 4H), 2.69–2.64
(m, 4H), 2.27–2.27 (m, 4H), 1.99 (m, 4H), 1.80 (m, 6H), 1.43 (m,
12H);13C NMR (75 MHz, CD3OD) d 154.9, 122.8, 122.7, 122.4,
53.4, 37.4, 36.7, 34.3, 27.4, 27.3, 22.6; HRMS (ESI) calculated for
C25H38N9 (MH+) 463.3172, found 463.3164.
(C4.) Methylenecyclopentyl TAGE-triazole. 1H NMR
(300 MHz, CD3OD at 3.31 ppm) d 7.70 (s, 2H), 4.42 (m, 4H),
2.68 (d, J = 7.2, 4H), 2.33–2.12 (m, 6H), 1.77–1.53 (m, 14H),
1.29–1.19 (m, 4H); 13C NMR (100 MHz, CD3OD) d 151.0, 149.1,
124.0, 121.7, 53.4, 41.5, 37.5, 33.5, 32.5, 30.7, 30.6, 27.3, 26.2,
22.7; HRMS (ESI) calculated for C25H38N9 (MH+) 463.3172,
found 463.3172.
(C5.) Methylenecyclohexyl TAGE-triazole. 1H NMR
(400 MHz, CD3OD at 3.31 ppm) d 7.69 (s, 2H), 4.50–4.36 (m,
4H), 2.65 (m, 4H), 2.56 (d, J = 6.8, 2H), 2.35–2.24 (m, 4H),
1.70–1.60 (m, 10H), 1.29–1.21 (m, 8H), 1.01–0.93 (m, 4H); 13C
NMR (100 MHz, CD3OD) d 151.0, 148.1, 124.3, 121.8, 53.4,
39.6, 37.5, 34.3, 34.2, 27.6, 27.4, 22.8; HRMS (ESI) calculated for
C27H42N9 (MH+) 491.3485, found 491.3483.
(P1.) Phenyl TAGE-triazole. 1H NMR (300 MHz, CD3OD at
3.31 ppm) d 8.37 (s, 2H), 7.80 (d, J = 5.1, 4H), 7.43 (t, J = 5.7,
4H), 7.36 (m, 2H), 4.60 (m, 4H), 2.80 (m, 1H), 2.75 (m, 1H),
2.57 (m, 2H), 2.41 (s, 1H), 2.39 (s, 1H); 13C NMR (75 MHz,
CD3OD) d 149.5, 149.2, 131.8, 130.1, 129.6, 126.9, 122.9, 121.7,
53.3, 37.0, 21.4; HRMS (ESI) calculated for C25H26N9 (MH+)
452.2305, found 452.2311.
(P2.) 4-Methoxyphenyl TAGE-triazole. 1H NMR (300 MHz,
CD3OD at 3.31 ppm) d 8.26 (s, 2H), 7.71 (d, J = 6.3 Hz, 4H),
6.98 (d, J = 6.6 Hz, 4H), 4.57 (m, 4H), 3.83 (s, 6H), 2.78 (m, 1H),
2.74 (m, 1H), 2.56 (m, 2H), 2.40 (s, 1H). 2.36 (s, 1H); 13C NMR
(100 MHz, DMSO-d6) d 162.5, 159.0, 146.3, 126.5, 123.2, 121.1,
117.0, 114.3, 55.2, 51.2, 34.8, 19.7; HRMS (ESI) calculated for
C27H30N9O2 (MH+) 512.2516, found 512.2520.
(P3.) Methylphenyl TAGE-triazole. 1H NMR (300 MHz,
CD3OD at 3.31 ppm) d 7.64 (s, 2H), 7.29–7.16 (m, 10H), 4.44–4.31
(m, 4H), 4.02 (s, 4H), 2.63 (m, 1H), 2.59 (m, 1H), 2.32 (m, 2H),
2.22 (s, 1H), 2.18 (s, 1H); 13C NMR (75 MHz, CD3OD) d 151.1,
148.8, 140.6, 129.8, 129.7, 127.7, 124.4, 121.8, 53.5, 37.4, 32.7,
22.6; HRMS (ESI) calculated for C27H30N9O2 (MH+) 479.2546,
found 479.2545.
(P4.) Ethylphenyl TAGE-triazole. 1H NMR (300 MHz,
CD3OD at 3.31 ppm) d 7.49 (s, 2H), 7.49-7.19 (m, 4H), 7.14
(m, 6H), 4.37 (m, 4H), 2.97 (m, 8H), 2.60 (m, 1H), 2.56 (m,
1H), 2.21–2.16 (m, 4H); 13C NMR (75 MHz, CD3OD) d 150.7,
148.7, 142.4, 129.7, 129.5, 127.3, 124.1, 121.6, 53.3, 37.3, 36.7,
28.3, 22.7; HRMS (ESI) calculated for C29H34N9 (MH+) 508.2931,
found 508.2923.
(P5.) Methylenephenoxy TAGE-triazole. 1H NMR (300 MHz,
CD3OD at 3.31 ppm) d 8.00 (s, 2H), 7.26 (m, 4H), 6.99–6.92 (m,
6H), 5.14 (s, 4H), 4.46 (m, 4H), 2.66 (m, 2H), 2.36 (m, 2H), 2.27
(s, 1H), 2.23 (s, 1H); 13C NMR (100 MHz, CD3OD) d 165.8,
164.6, 159.9, 145.5, 130.7, 125.9, 122.5, 116.2, 62.6, 53.6, 37.4,
22.7; HRMS (ESI) calculated for C27H28N9O2 (MH+) 510.2366,
found 510.2347.














































(A1.) Phenylamide TAGE-triazole. 1H NMR (400 MHz,
CD3OD at 3.31 ppm) d 7.90 (s, 2H), 7.83 (d, J = 7.2, 4H), 7.50
(t, J = 7.4, 2H), 7.42 (t, J = 7.4, 4H), 4.61 (s, 4H), 4.48–4.34 (m,
4H), 2.59 (bm, 2H), 2.36 (bm, 2H), 2.24 (bm, 1H), 2.20 (bm, 1H);
13C NMR (100 MHz, CD3OD) d 170.2, 150.3, 146.8, 135.4, 133.0,
129.7, 128.5, 125.0, 120.9, 53.3, 37.2, 36.3, 22.2 HRMS (ESI)
calculated for C29H32N11O2 (MH+) 565.2661, found 565.2661.
(A2.) Pyrrole TAGE-triazole. 1H NMR (300 MHz, CD3OD
at 3.31 ppm) d 7.86 (s, 2H), 6.90 (s, 2H), 6.82 (d, J = 2.7 Hz,
2H), 6.13 (t, J = 3.2 Hz, 2H), 4.56 (s, 4H), 4.46–4.37 (m, 4H),
2.57 (m, 2H), 2.36 (bm, 2H), 2.25 (bm, 1H), 2.19 (bm, 1H); 13C
NMR (75 MHz, CD3OD) d 163.8, 149.1, 147.3, 126.7, 125.0, 123.4,
119.2, 112.5, 110.5, 53.0, 36.8, 35.6, 21.2; HRMS (ESI) calculated
for C25H30N13O2 (MH+) 543.2567, found 543.2560.
(A3.) Bromopyrrole TAGE-triazole. 1H NMR (400 MHz,
CD3OD at 3.31 ppm) d 7.91 (s, 2H), 6.93 (s, 2H), 6.81 (s, 2H),
4.57 (s, 4H), 4.56–4.35 (m, 4H), 2.65 (bm, 2H), 2.42 (bm, 2H),
2.31 (m, 1H), 2.27 (m, 1H); 13C NMR (100 MHz, CD3OD) d
162.6, 148.9, 147.1, 127.4, 125.1, 123.2, 119.0, 113.9, 97.7, 53.0,
36.7, 35.7, 21.1; HRMS (ESI) calculated for C25H27N13O2Br2Na
(MNa+) 722.0675, found 722.0669.
(A4.) Dibromopyrrole TAGE-triazole. 1H NMR (400 MHz,
CD3OD at 3.31 ppm) d 7.93 (s, 2H), 6.86 (s, 2H), 4.56 (s, 4H),
4.55–4.40 (m, 4H), 2.65 (m, 2H), 2.41 (bm, 2H), 2.28 (bm, 2H);
13C NMR (100 MHz, CD3OD) d 161.8, 149.0, 147.0, 128.7, 125.0,
119.1, 114.9, 106.5, 100.2, 53.0, 36.8, 35.8, 21.2; HRMS (ESI)
calculated for C25H26N13O2Br4 (MH+) 855.9060, found 855.9035.
N-(Prop-2-ynyl)benzamide. This compound has been previ-
ously reported. For this study it was synthesized in accordance
with the procedure in ref. 27.
General procedure for acylation of propargyl amine
with pyrrole derivatives
Propargyl amine (300 mL) was added to a stirring solution of
the desired 2-(trichloroacetyl)-pyrrole (0.95 equiv) with Na2CO3
(3 equiv) in methylene chloride at room temperature. The reaction
was allowed to run overnight. Brine was then added to quench the
reaction and the contents were then transferred to a separatory
funnel. Ethyl acetate was used to extract the product and the
organic layer was washed with brine (3x). The organic layers
were then combined, dried with sodium sulfate and concentrated.
The resulting solid was recrystallized in methylene chloride
to give yields of 65–80%. The resulting propargyl amides are
characterized below.
N-(Prop-2-ynyl)-1H-pyrrole-2-carboxyamide. 1H NMR
(400 MHz, CD3OD at 3.31 ppm) d 6.91 (m, 1H), 6.79 (m, 1H),
6.16 (m, 1H), 4.09 (d, J = 2.0 Hz, 2H), 2.56 (t, J = 2.2 Hz, 1H);
13C NMR (75 MHz, CD3OD) d 163.5, 126.6, 123.3, 112.2, 110.4,
81.2, 72.0, 29.4; HRMS (ESI) calculated for C8H9N2O (MH+)
149.0709, found 149.0708.
4-Bromo-N -(prop-2-ynyl)-1H -pyrrole-2-carboxyamide. 1H
NMR (300 MHz, CD3OD at 3.31 ppm) d 6.92 (s, 1H), 6.78 (s,
1H), 4.08 (d, J = 2.1 Hz, 2H), 2.57 (t, J = 2.3 Hz, 1H); 13C NMR
(75 MHz, CD3OD) d 162.2, 127.3, 123.2, 113.7, 97.6, 81.0, 72.1,
29.4; HRMS (ESI) calculated for C8H8N2OBr (MH+) 225.9742,
found 225.9744.
4,5-Dibromo-N-(prop-2-ynyl)-1H-pyrrole-2-carboxyamide. 1H
NMR (400 MHz, CD3OD at 3.31 ppm) d 6.82 (s, 1H), 4.08 (d,
J = 2.4 Hz, 2H), 2.58 (t, J = 2.7 Hz, 1H); 13C NMR (100 MHz,
CD3OD) d 161.4, 128.6, 114.7, 106.6, 100.2, 80.9, 72.2, 29.4;
HRMS (ESI) calculated for C8H7N2OBr2 (MH+) 304.8919, found
304.8924.
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